Cambridge Investment Research Advisors, Inc. Editas Medicine, Inc. Transaction History

Cambridge Investment Research Advisors, Inc.

$29.9 Billion
Q4 2024

A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 86,347 shares of EDIT stock, worth $165,786. This represents 0.0% of its overall portfolio holdings.

Number of Shares

86,347

Previous 74,421 16.03%

Holding current value

$165,786

Previous $254,000 56.69%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$1.2 - $3.76 $14,311 - $44,841	11,926 Added 16.03%	86,347 $110,000
Q3 2024 Oct 28, 2024	BUY	$3.39 - $5.96 $1,606 - $2,825	474 Added 0.64%	74,421 $254,000
Q2 2024 Jul 26, 2024	SELL	$4.67 - $7.28 $15,574 - $24,278	-3,335 Reduced 4.32%	73,947 $345,000
Q1 2024 Apr 24, 2024	SELL	$7.03 - $11.07 $16,640 - $26,202	-2,367 Reduced 2.97%	77,282 $573,000
Q4 2023 Feb 09, 2024	BUY	$6.25 - $11.11 $26,275 - $46,706	4,204 Added 5.57%	79,649 $807,000
Q3 2023 Oct 24, 2023	BUY	$6.92 - $9.31 $16,974 - $22,837	2,453 Added 3.36%	75,445 $588,000
Q2 2023 Jul 13, 2023	BUY	$6.36 - $11.47 $52,425 - $94,547	8,243 Added 12.73%	72,992 $601,000
Q1 2023 May 11, 2023	BUY	$7.03 - $11.53 $5,075 - $8,324	722 Added 1.13%	64,749 $469,000
Q4 2022 Feb 08, 2023	SELL	$8.32 - $13.21 $20,334 - $32,285	-2,444 Reduced 3.68%	64,027 $568,000
Q3 2022 Oct 17, 2022	BUY	$12.16 - $19.42 $14,093 - $22,507	1,159 Added 1.77%	66,471 $813,000
Q2 2022 Jul 13, 2022	BUY	$9.99 - $21.35 $7,512 - $16,055	752 Added 1.16%	65,312 $772,000
Q1 2022 May 12, 2022	SELL	$14.08 - $27.63 $18,529 - $36,361	-1,316 Reduced 2.0%	64,560 $1.23 Million
Q4 2021 Feb 03, 2022	SELL	$26.55 - $40.57 $2.96 Million - $4.52 Million	-111,405 Reduced 62.84%	65,876 $1.75 Million
Q3 2021 Nov 02, 2021	BUY	$39.27 - $72.94 $3.22 Million - $5.98 Million	82,042 Added 86.14%	177,281 $7.28 Million
Q2 2021 Aug 10, 2021	BUY	$31.29 - $56.64 $12,547 - $22,712	401 Added 0.42%	95,239 $5.39 Million
Q1 2021 May 07, 2021	SELL	$39.71 - $90.58 $261,530 - $596,559	-6,586 Reduced 6.49%	94,838 $3.98 Million
Q4 2020 Feb 04, 2021	BUY	$27.07 - $84.35 $2.49 Million - $7.75 Million	91,908 Added 965.83%	101,424 $7.11 Million
Q3 2020 Oct 29, 2020	SELL	$28.06 - $37.16 $142,853 - $189,181	-5,091 Reduced 34.85%	9,516 $267,000
Q2 2020 Jul 27, 2020	BUY	$18.5 - $34.34 $34,909 - $64,799	1,887 Added 14.83%	14,607 $432,000
Q1 2020 May 08, 2020	BUY	$14.88 - $32.78 $74,578 - $164,293	5,012 Added 65.02%	12,720 $252,000
Q4 2019 Feb 04, 2020	BUY	$19.49 - $32.63 $150,228 - $251,512	7,708 New	7,708 $228,000
Q3 2018 Nov 02, 2018	SELL	$27.65 - $38.39 $154,674 - $214,753	-5,594 Closed	0 $0
Q2 2018 Aug 10, 2018	SELL	$31.4 - $41.01 $20,284 - $26,492	-646 Reduced 10.35%	5,594 $0
Q1 2018 May 09, 2018	BUY	$29.84 - $44.08 $186,201 - $275,059	6,240 New	6,240 $0

Others Institutions Holding EDIT

# of Institutions

225

Shares Held

54.2M

Call Options Held

412K

Put Options Held

355K

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $132M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Account

Cambridge Investment Research Advisors, Inc. Editas Medicine, Inc. Transaction History